Niacin,
does it really help with Cholesterol and lipids?
research showsPharmacologic-dose nicotinic acid changes lipid values such as HDL, triglycerides, and LDL, but these are surrogate markers. In the large independent RCTs AIM-HIGH (Boden 2011) and HPS2-THRIVE (Landray 2014), adding niacin on a background of statin therapy did not reduce major cardiovascular events, and in HPS2-THRIVE adverse reactions such as increased blood glucose, infections, and bleeding increased. A 2017 Cochrane review also summarized that evidence for cardiovascular benefit was insufficient. The narrow phrase lipid-value improvement may be true, but cardiovascular risk-management claims are contradicted by large clinical-outcome trials.
ads claimKorean-language products and content connect niacin with 'cholesterol,' 'blood flow,' 'energy metabolism,' 'skin flushing,' 'NAD precursor,' and 'metabolic health.' Some explanations present the niacin content of ordinary B-complex products and pharmacologic doses for lipid improvement as if they had the same meaning.
Useful facts when choosing a product
- The nicotinic acid dose in lipid-improvement studies is usually 1-3 g/day, which differs greatly from ordinary vitamin B3 nutrient supplementation.
- Nicotinamide is the same vitamin B3 but differs from nicotinic acid, the form expected to have pharmacologic lipid-improvement effects.
- High-dose niacin can be associated with flushing, itching, gastrointestinal symptoms, elevated liver enzymes, hepatotoxicity, worsening blood glucose, and worsening gout.
- In AIM-HIGH and HPS2-THRIVE, changes in lipid values did not lead to reductions in major cardiovascular events.
- General health functional food listed claims are nutrient functions such as energy production and are distinct from cardiovascular-event prevention or lipid-treatment effects.
What the research actually shows
At pharmacologic doses of 500-3000 mg/day, niacin raises HDL and lowers triglycerides and LDL. AIM-HIGH added extended-release niacin 1,500-2,000 mg/day to statins in 3,414 patients with ASCVD, but it failed to reduce primary cardiovascular events and was stopped early. HPS2-THRIVE, in more than 25,000 high-risk patients, found that extended-release niacin plus laropiprant did not reduce major vascular events and increased serious adverse reactions such as increased blood glucose, diabetes-related problems, infections, and bleeding. A 2017 Cochrane review summarized that niacin did not reduce death, myocardial infarction, or stroke.
Why this is classified as D (36)
D. Although lipid-value changes from pharmacologic-dose nicotinic acid are confirmed, adding niacin on a statin background failed to reduce major cardiovascular events in AIM-HIGH and HPS2-THRIVE. The 2017 Cochrane review also does not support cardiovascular benefit, so under methodology v0.6 rule 2, cardiovascular risk-management claims are lowered to D.
Counterpoint. If narrowed only to 'improving lipid values,' there is a factual component. But when 'cholesterol management' is read as meaning reduced cardiovascular risk, evidence from large clinical endpoints is negative.
Rejudgment record. Final reassessment — Methodology v0.6 rule 2 applied. In AIM-HIGH and HPS2-THRIVE, the primary clinical endpoints for adding niacin on a statin background were null, and adverse reactions increased.
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Boden WE et al. 2011 (AIM-HIGH) | Large randomized double-blind RCT | 3,414 | Supported by NHLBI, Abbott, and Merck | Major cardiovascular events | HDL/triglycerides improved, but primary cardiovascular events were not reduced, at 16.4% vs 16.2%. | Core |
| Landray MJ et al. 2014 (HPS2-THRIVE) | Large randomized RCT | 25,673 | Industry/research support including Merck | Major vascular events | Extended-release niacin plus laropiprant did not reduce major vascular events and increased serious adverse reactions. | Core |
| Schandelmaier S et al. 2017 | Cochrane systematic review | 39,195 | Independent/public | Death, myocardial infarction, and stroke | Niacin did not reduce all-cause mortality, cardiovascular mortality, myocardial infarction, or stroke. | Core |
| Bruckert E et al. 2010 | Meta-analysis | Unknown | Cardiovascular events and lipids | Earlier studies suggested a possibility of event reduction, but this was not confirmed in later large statin-combination RCTs. | Supporting |
Receipt — 4 References
Every cited source was opened and checked against the live page on 2026-07-09.
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-09 · Corrections: none
Cite this verdict
[Chamgap] Niacin (vitamin B3) × Cholesterol and lipids — Evidence Grade D·36. 4 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/heart/niacin-lipids/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.